Assessment of luteolin (3′,4′,5,7-tetrahydroxyflavone) neuropharmacological activity

Behavioural Brain Research

Volumn 189, Issue 1, 2008, Pages 75-82

  Coleta, Miguel ^a   Campos, Maria Graça ^a   Cotrim, Maria Dulce ^a   Lima, Thereza Christina M de ^b   Cunha, António Proença da ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CCB   (Brazil)

Author keywords

Anxiolytics; Central nervous system; Flavones; Flavonoids; GABA; Luteolin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; APIGENIN; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; CHRYSIN; FLAVONE DERIVATIVE; LIGAND; LUTEOLIN; WOGONIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CATALEPSY; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; ELECTRIC SHOCK; FORCED SWIMMING TEST; GABAERGIC SYSTEM; GLYCOSYLATION; LIGAND BINDING; MALE; MAZE TEST; MOTOR PERFORMANCE; MOUSE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECTUM TEMPERATURE; RIGHTING REFLEX; TRANQUILIZING ACTIVITY;

ANIMALS; ANTICONVULSANTS; ANXIETY; BRAIN; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; EXPLORATORY BEHAVIOR; FLAVONOIDS; FREEZING REACTION, CATALEPTIC; HYPNOTICS AND SEDATIVES; LUTEOLIN; MALE; MICE; MOTOR ACTIVITY; RECEPTORS, DOPAMINE; RECEPTORS, GABA-A; REFLEX;

EID: 40849102404     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.12.010     Document Type: Article

References (68)

1. Harborne J.B., and Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 55 6 (2000) 481-504
2. Karakaya S., and Sedef N.E.L. Quercetin, luteolin, apigenin and kaempferol contents of some foods. Food Chem 66 3 (1999) 289-292
3. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 4 (2000) 673-751
4. A receptor complex. Curr Drug Targets CNS Neurol Disord 4 5 (2005) 575-585
5. Marder M., and Paladini A.C. GABA(A)-receptor ligands of flavonoid structure. Curr Top Med Chem 2 8 (2002) 853-867
6. Paladini A.C., Marder M., Viola H., Wolfman C., Wasowski C., and Medina J.H. Flavonoids and the central nervous system: from forgotten factors to potent anxiolytic compounds. J Pharm Pharmacol 51 5 (1999) 519-526
7. Nielsen M., Frokjaer S., and Braestrup C. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem Pharmacol 37 17 (1988) 3285-3287
8. Medina J.H., Pena C., Levi de Stein M., Wolfman C., and Paladini A.C. Benzodiazepine-like molecules, as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem Biophys Res Commun 165 2 (1989) 547-553
9. Huang X., Liu T., Gu J., Luo X., Ji R., Cao Y., et al. 3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors. J Med Chem 44 12 (2001) 1883-1891
10. Dekermendjian K., Kahnberg P., Witt M.R., Sterner O., Nielsen M., and Liljefors T. Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex. J Med Chem 42 21 (1999) 4343-4350
11. Marder M., Estiu G., Blanch L.B., Viola H., Wasowski C., Medina J.H., et al. Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA(A) receptor complex. Bioorg Med Chem 9 2 (2001) 323-335
12. Hong X., and Hopfinger A.J. 3D-pharmacophores of flavonoid binding at the benzodiazepine GABA(A) receptor site using 4D-QSAR analysis. J Chem Inf Comput Sci 43 1 (2003) 324-336
13. Medina J.H., Viola H., Wolfman C., Marder M., Wasowski C., Calvo D., et al. Overview-flavonoids: a new family of benzodiazepine receptor ligands. Neurochem Res 22 4 (1997) 419-425
14. Wang F., Xu Z., Yuen C.T., Chow C.Y., Lui Y.L., Tsang S.Y., et al. 6,2′-Dihydroxyflavone, a subtype-selective partial inverse agonist of GABA(A) receptor benzodiazepine site. Neuropharmacology 53 4 (2007) 574-582
15. Griebel G., Perrault G., Tan S., Schoemaker H., and Sanger D.J. Pharmacological studies on synthetic flavonoids: comparison with diazepam. Neuropharmacology 38 7 (1999) 965-977
16. Viola H., Wasowski C., Levi de Stein M., Wolfman C., Silveira R., Dajas F., et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 61 3 (1995) 213-216
17. Avallone R., Zanoli P., Puia G., Kleinschnitz M., Schreier P., and Baraldi M. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol 59 11 (2000) 1387-1394
18. Wolfman C., Viola H., Paladini A., Dajas F., and Medina J.H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 47 1 (1994) 1-4
19. Hui K.M., Huen M.S., Wang H.Y., Zheng H., Sigel E., Baur R., et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 64 9 (2002) 1415-1424
20. Medina J.H., Paladini A.C., Wolfman C., Levi de Stein M., Calvo D., Diaz L.E., et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 40 10 (1990) 2227-2231
21. Viola H., Wolfman C., Levi de Stein M., Wasowski C., Peña C., Medina J.H., et al. Isolation of pharmacologically active benzodiazepine receptor ligands from Tilia tomentosa (Tiliaceae). J Ethnopharmacol 44 1 (1994) 47-53
22. Okuyama E., Okamoto Y., Yamazaki M., and Satake M. Pharmacologically active components of a Peruvian medicinal plant, huanarpo (Jatropha cilliata). Chem Pharm Bull (Tokyo) 44 2 (1996) 333-336
23. Marder M., Viola H., Wasowski C., Wolfman C., Waterman P.G., Medina J.H., et al. Cirsiliol and caffeic acid ethyl ester, isolated from Salvia guaranitica are competitive ligands from the central benzodiazepine receptors. Phytomedicine 3 1 (1996) 29-31
24. Peng W.H., Hsieh M.T., Lee Y.S., Lin Y.C., and Liao J. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. J Ethnopharmacol 72 3 (2000) 435-441
25. Coleta M., Batista M.T., Campos M.G., Carvalho R., Cotrim M.D., Lima T.C., et al. Neuropharmacological evaluation of the putative anxiolytic effects of Passiflora edulis Sims, its sub-fractions and flavonoid constituents. Phytother Res 20 12 (2006) 1067-1073
26. Fernández S.P., Wasowski C., Loscalzo L.M., Granger R.E., Johnston G.A.R., Paladini A.C., et al. Central nervous system depressant action of flavonoid glycosides. Eur J Pharmacol 539 3 (2006) 168-176
27. Goutman J.D., Waxemberg M.D., Doñate-Oliver F., Pomata P.E., and Calvo D.J. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. Eur J Pharmacol 461 2-3 (2003) 79-87
28. Boissier J.R., Dremont C., Robbins R., and Pagny J. Tentative de pharmacologie previsionelle dans la domaine des neuroleptiques: actions sédative centralle et adrenolitique de la N(dimethoxy-3,4 phenethyl) N(chloro-2 phenyl) piperazine. Arch Int Pharmacodyn Ther 133 (1961) 29-32
29. Dunham N.W., and Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 46 3 (1957) 208-209
30. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 (1987) 180-185
31. Rodgers R.J., and Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21 6 (1997) 801-810
32. Pellow S., Chopin P., File S.E., and Briley M. Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
33. File S.E., and Wardill A.G. The reliability of the hole-board apparatus. Psychopharmacologia 44 1 (1975) 47-51
34. Carlini E.A., Contar J.D.P., Silva-Filho A.R., Silveira-Filho N.G., Frochtengarten M.L., and Bueno O.F. Pharmacology of lemongrass (Cymbopogon citratus Stapf). I. Effects of teas prepared from the leaves on the laboratory animals. J Ethnopharmacol 17 (1986) 37-64
35. Randrup A., and Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia 11 (1967) 300-310
36. Swinyard E.A., Brown W.C., and Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106 3 (1952) 319-330
37. Porsolt L.D., Anton G., Blavet N., and Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47 (1978) 379-391
38. Cavadas C., Araujo I., Cotrim M.D., Amaral T., Cunha A.P., and Macedo T. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung 45 (1995) 753-755
39. Rodgers R.J., and Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper S.J., and Hendrie C.A. (Eds). Ethology and Psychopharmacology (1994), John Wiley & Sons Ltd., New York 9-44
40. Lolli L.F., Sato C.M., Romanini C.V., Villas-Boas L.B., Santos C.A.M., and Oliveira R.M.W. Possible involvement of GABAA-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice. J Ethnopharmacol 111 2 (2007) 308-314
41. Cryan J.F., Kelly P.H., Chaperon F., Gentsch C., Mombereau C., Lingenhoehl K., et al. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310 (2004) 952-963
42. Zhao X., Cui X.Y., Chen B.Q., Chu Q.P., Yao H.Y., Ku B.S., et al. Tetrandrine, a bisbenzylisoquinoline alkaloid from Chinese herb Radix, augmented the hypnotic effect of pentobarbital through serotonergic system. Eur J Pharmacol 506 2 (2004) 101-105
43. Rogawski M.A. Mechanism-specific pathways for new antiepileptic drug discovery. In: French J., Leppik I., and Dichter M.A. (Eds). Antiepileptic drug development, advances in neurology vol. 76 (1998), Lippincott-Raven Publishers, Philadelphia (PA) 11-27
44. Fisas M.A., Farré A., Camarasa J., and Escubedo E. Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors. Pharmacology 72 (2004) 57-67
45. Gyertyán I., and Sághy K. The selective dopamine D(3) receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572 2-3 (2007) 171-174
46. Haleem D.J., Samad N., and Haleem M.A. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. Behav Pharmacol 18 2 (2007) 147-153
47. Neal-Beliveau B.S., Joyce J.N., and Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265 (1993) 207-217
48. Erzin-Waters C., Muller P., and Seeman P. Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. Can J Physiol Pharmacol 54 4 (1976) 516-519
49. Hauber W., Neuscheler P., Nagel J., and Müller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate-putamen of rats. Eur J Neurosci 14 8 (2001) 1287-1293
50. Skilbeck K.J., O'Reilly J.N., Johnston G.A., and Hinton T. The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined. Schizophr Res 90 1-3 (2007) 76-80
51. Ågmo A., Belzung C., and Giordano M. Interactions between dopamine and GABA in the control of ambulatory activity. J Neural Transm 103 8-9 (1996) 925-934
52. Keller H.H., Schaffner R., and Haefely W. Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 294 1 (1976) 1-7
53. Worms P., and Lloyd K.G. Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol 311 2 (1980) 179-184
54. Malec D., and Langwiński R. The influence of gabaergic system on cataleptogenic action of analgesics and haloperidol. Pol J Pharmacol Pharm 38 5-6 (1986) 501-507
55. Naidu P.S., and Kulkarni S.K. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. Methods Find Exp Clin Pharmacol 26 5 (2004) 323
56. Santos K.C., Santos C.A.M., and Oliveira R.M.W. Passiflora actinia Hooker extracts and fractions induce catalepsy in mice. J Ethnopharmacol 100 3 (2005) 306-309
57. Quéva C., Bremner-Danielsen M., Edlund A., Ekstrand J., Elg S., Erickson S., et al. Effects of GABA agonists on body temperature regulation in GABAB(1)-/- mice. Br J Pharmacol 140 (2003) 315-322
58. Takeda H., Tsuji M., and Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350 1 (1998) 21-29
59. Rego J.C., Viana A.F., Le Maître E., Deniel A., Rates S.M.K., Leroux-Nicollet I., et al. Comparisons between anxiety tests for selection of anxious and non anxious mice. Behav Brain Res 169 2 (2006) 282-288
60. Andrews N., and File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 235 1 (1993) 109-112
61. File S.E. Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 9 (1985) 113-122
62. Calil C.M., and Marcondes F.K. The comparison of immobility time in experimental rat swimming models. Life Sci 79 18 (2006) 1712-1719
63. Flugy A., Gagliano M., Cannizzaro C., Novara V., and Cannizzaro G. Antidepressant and anxiolytic effects of alprazolam versus the conventional. antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. Eur J Pharmacol 214 2-3 (1992) 233-238
64. Nakazawa T., Yasuda T., Ueda J., and Ohsawa K. Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biol Pharm Bull 26 4 (2003) 474
65. Clenet F., Hascoet M., Fillion G., Galons H., and Bourin M. Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 158 2 (2005) 339-348
66. Starr K.R., Price G.W., Watson J.M., Atkinson P.J., Arban R., Melotto S., et al. SB-649915-B, a novel 5-HT(1A/B) autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology 32 (2007) 2163-2172
67. Manach C., and Donovan J.L. Pharmacokinetics of dietary flavonoids in humans. Free Radic Res 38 8 (2004) 771-785
68. Shimoi K., Okada H., Furugori M., Goda T., Takase S., Suzuki M., et al. Intestinal absorption of luteolin and luteolin 7-O-β-glucoside in rats and humans. FEBS Lett 438 (1998) 220-224